← Leaderboards
Emily A Kendall
Johns Hopkins University
$5,217,479
Attributed
$6,330,471
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2017–25$2M$1.5M$1M$500K$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,330,471 · 3
By mechanism
R01$5,451,091 · 2
K08$879,380 · 1
Top collaborators
- David Wesley Dowdy4 shared
Most similar at Johns Hopkins University
Same institution · by research overlap
- David Wesley Dowdy$17,286,098
- Sharon A Nachman$214,342,272
- Philippa Musoke$9,335,883
- Vivian F. Go$15,157,279
- Eric L Nuermberger$20,859,483
Others in their field
Other Emerging Leaders on “Transmission Process”
- Scott Hensley · University Of Pennsylvania$49,758,212
- Thomas Denny · Duke University$22,999,550
- S. Mark Tompkins · University Of Georgia$20,806,329
- Walter Orenstein · Emory University$15,988,348
- Andrew Pekosz · Johns Hopkins University$15,027,681
- Esther M. Friedman · University Of Michigan At Ann Arbor$10,105,179
Research focus
Transmission ProcessTuberculosisPublic HealthSputumEpidemiologyCommunicable DiseasesProgramsMolecularPreferenceHigh RiskCase FindingInfectionPrevalenceInvestigationImmunologicsMycobacterium TuberculosisCharacteristicsClinical Decision-MakingFutureEvaluationCommunitiesDiagnosticCessation Of LifeEarly Diagnosis
Grant awards (14)
Hotspot versus clinic-based active case finding for TB in Uganda: A pragmatic randomized trial$576,980
R01 · FY2025 · HL · contact PI
Who are the Ultra-positive, culture-negative? Understanding the trajectories of individuals in Uganda with trace M. tuberculosis nucleic acid in sputum$718,579
R01 · FY2024 · HL · contact PI
Hotspot versus clinic-based active case finding for TB in Uganda: A pragmatic randomized trial$560,353
R01 · FY2024 · HL · contact PI
Who are the Ultra-positive, culture-negative? Understanding the trajectories of individuals in Uganda with trace M. tuberculosis nucleic acid in sputum$629,170
R01 · FY2023 · HL · contact PI
Hotspot versus clinic-based active case finding for TB in Uganda: A pragmatic randomized trial$544,637
R01 · FY2023 · HL · contact PI
Who are the Ultra-positive, culture-negative? Understanding the trajectories of individuals in Uganda with trace M. tuberculosis nucleic acid in sputum$638,033
R01 · FY2022 · HL · contact PI
Hotspot versus clinic-based active case finding for TB in Uganda: A pragmatic randomized trial$544,014
R01 · FY2022 · HL · contact PI
Who are the Ultra-positive, culture-negative? Understanding the trajectories of individuals in Uganda with trace M. tuberculosis nucleic acid in sputum$611,836
R01 · FY2021 · HL · contact PI
Translational modeling of individual- and population-level outcomes of novel tuberculosis drug regimens$147,787
K08 · FY2021 · AI · contact PI
Who are the Ultra-positive, culture-negative? Understanding the trajectories of individuals in Uganda with trace M. tuberculosis nucleic acid in sputum$627,489
R01 · FY2020 · HL · contact PI
Translational modeling of individual- and population-level outcomes of novel tuberculosis drug regimens$147,550
K08 · FY2020 · AI · contact PI
Translational modeling of individual- and population-level outcomes of novel tuberculosis drug regimens$194,681
K08 · FY2019 · AI · contact PI
Translational modeling of individual- and population-level outcomes of novel tuberculosis drug regimens$194,681
K08 · FY2018 · AI · contact PI
Translational modeling of individual- and population-level outcomes of novel tuberculosis drug regimens$194,681
K08 · FY2017 · AI · contact PI